SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. 1. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 94050.
  • 2
    Berden JH. Lupus nephritis. Kidney Int 1997; 52: 53858.
  • 3
    Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine (Baltimore) 1999; 78: 14866.
  • 4
    Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984; 311: 152833.
  • 5
    Austin HA, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 6149.
  • 6
    Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 94550.
  • 7
    Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM, The Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 13739.
  • 8
    Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 7415.
  • 9
    Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 54957.
  • 10
    Illei GG, Austin HA, Crane MA, Collins L, Gourley ME, Yarboro CH, et al. Combining pulse cyclophosphamide with pulse methylprednisolone improves long-term renal outcome in patients with lupus nephritis without added toxicity. Ann Intern Med 2001; 135: 24857.
  • 11
    D'Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997; 15: 27582.
  • 12
    Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 2437.
  • 13
    Belmont HM, Storch M, Buyon J, Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995; 4: 1048.
  • 14
    Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 8339.
  • 15
    Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, Hong Kong–Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 115662.
  • 16
    Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998; 129: 10315.
  • 17
    Gur-Lavi M. Long-term remission with allogenic bone marrow transplantation in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1777.
  • 18
    Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000; 356: 7017.
  • 19
    Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994; 24: 15971.
  • 20
    Dooley MA, Hogan S, Jennette C, Falk R, Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 118895.
  • 21
    Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999; 92: 2118.
  • 22
    Ioannidis JPA, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 25864.
  • 23
    Illei GG, Takada K, Parkin D, Austin HA, Crane NP, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 9951002.
  • 24
    Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 3669.
  • 25
    Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 204753.
  • 26
    Balow JE, Boumpas DT, Austin HA III. New prospects for treatment of lupus nephritis. Semin Nephrol 2000; 20: 329.
  • 27
    Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 147080.
  • 28
    Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998; 160: 215865.
  • 29
    Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159: 31048.
  • 30
    Biancone L, Andres G, Ahn H, DeMartino C, Stamenkovic I. Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis. Kidney Int 1995; 48: 45868.
  • 31
    Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 206373.
  • 32
    Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 82637.
  • 33
    Yellin MJ, D'Agati V, Parkinson G, Han AS, Szema A, Baum D, et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997; 40: 12434.
  • 34
    Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95101.
  • 35
    Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 94755.
  • 36
    Van Kooten C, Gerritsma JS, Paape ME, van Es LA, Banchereau J, Daha MR. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997; 51: 71121.
  • 37
    Kuroiwa T, Lee EG, Danning CL, Illei GG, McInnes IB, Boumpas DT. CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. J Immunol 1999; 163: 216875.
  • 38
    Kuroiwa TK, Schlimgen R, Illei GG, McInnes IB, Boumpas DT. Distinct T cell/renal tubular epithelial interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritis. J Immunol 2000; 164: 33239.
  • 39
    Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 922.
  • 40
    Pammer J, Plettenberg A, Weninger W, Diller B, Mildner M, Uthman A, et al. CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma. Am J Pathol 1996; 148: 138795.
  • 41
    Yellin MJ, Winikoff S, Fortune SM, Baum D, Crow MK, Lederman S, et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 1995; 58: 20916.
  • 42
    Karmann K, Min W, Fanslow WC, Pober JS. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. J Exp Med 1996; 184: 17382.
  • 43
    Yellin MJ, Brett J, Baum D, Matsushima A, Szabolcs M, Stern D, et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med 1995; 182: 185764.
  • 44
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 45
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 46
    Petri M, Buyon J, Skovorn ML. Reliability of SELENA SLEDAI and flare as clinical trial outcome measures [abstract]. Lupus 1998; 7 Suppl: 110.
  • 47
    Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
  • 48
    Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 6229.
  • 49
    Austin HA III. Clinical evaluation and monitoring of lupus nephritis. Lupus 1998; 7: 61822.
  • 50
    Levey AS, Lan SP, Corwin HL, Kasinath BS, Lackin J, Neilson EG, et al. Progression and remission of renal disease in the lupus nephritis collaborative study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116: 11423.
  • 51
    Fraenkel L, MacKenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM. Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol 1994; 21: 20527.
  • 52
    Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 155462.
  • 53
    Grammer AC, Shinohara S, Vasquez E, Gur H, Illei G, Lipsky PE. Normalization of peripheral B cells following treatment of active SLE patients with humanized anti-CD154 Mab (5C8, BG9588) [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S282.
  • 54
    Gur H, Lipsky PE, Shinohara S, Vasquez E, Illei G, Grammer AC. Analysis of CD5 expression on peripheral B cells following treatment of active SLE patients with humanized anti-CD154 mAb (5C8, BG9588) [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S282.
  • 55
    Grammer AC, Lipsky PE. CD154–CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 141729.
  • 56
    Kalled SL, Cuttler AH, Burky LC. Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. J Immunol 2001; 157: 17407.
  • 57
    Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol 1996; 157: 315964.
  • 58
    Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998; 101: 36471.
  • 59
    Lawson BR, Prud-homme GJ, Chang Y, Gardner HA, Kuan J, Kono DH, et al. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest 2000; 106: 20715.
  • 60
    Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv Immunol 1996; 63: 438.
  • 61
    Kirk DA, Burkly CL, Batty DS, Baumgartner ER, Berning DJ, Buchanan K, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 68693.
  • 62
    Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 53941.
  • 63
    Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72: 291300.
  • 64
    Funakoshi S, Taub DD, Anver MR, Raziuddin A, Asai O, Reddy V, et al. Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. J Clin Invest 1997; 99: 48491.
  • 65
    Henn V, Slupsky RJ, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 5914.
  • 66
    Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [letter]. Nat Med 2000; 6: 114.
  • 67
    IDEC Pharmaceuticals Web site. Accessed Jan. 20, 2003. URL: http://www.idecpharm.com/site/science/idec131.htm.
  • 68
    Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 24752.